Skip to content
Screener

Zoetis ZTS Q4 2025 Annual earnings

Reported February 12, 2026 · Before market open

Revenue$2.4BBeat by $27.0M
EPS$1.48Beat by $0.08
Revenue estimate$2.4B
EPS estimate$1.40

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$2.3B
EPS estimate$1.51

Financials

Q4 2025

Income statement

See full
Revenue$2.4B+3.0%
Gross profit$1.7B+4.0%
Net income$603.0M+3.8%
EPS (diluted)$1.37+6.2%

Balance sheet

See full
Cash & equivalents$2.5B+15.9%
Total debt$9.3B+70.5%
Total equity$3.4B-28.4%
Total assets$15.5B+8.8%

Cash flow

See full
Operating cash flow$893.0M-1.3%
CapEx$161.0M-25.5%
Free cash flow$732.0M+6.2%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$55.45B-24.6%
Enterprise value$62.3B-18.9%
P/E20.9×-8.7×
P/S5.9×-2.1×

Profitability

See full
Gross margin71.7%+1.1pp
Net margin28%+1.2pp
FCF margin24.1%-0.7pp

Returns & leverage

See full
Return on equity64.8%+13.9pp
Debt / equity2.7×+1.6×
Current ratio3.1×+1.4×

Segments

By product

See full
Parasiticides$542.0M+4.4%
Vaccines$512.0M+10.8%
Dermatology$429.0M+1.9%
Anti-infectives$284.0M+1.1%
Pain and sedation$209.0M-3.7%

By segment

See full
U.S.$1.2B-1.7%
International$1.1B+7.9%

FAQ

When did Zoetis report Q4 2025 earnings?
Zoetis (ZTS) reported Q4 2025 earnings on February 12, 2026 before market open.
What were Zoetis's Q4 2025 revenue and EPS?
Zoetis reported revenue of $2.4B and eps of $1.48 for Q4 2025.
Did Zoetis beat estimates in Q4 2025?
Revenue beat the consensus estimate of $2.4B by $27.0M. EPS beat the consensus estimate of $1.40 by $0.08.
How did Zoetis's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 3.0% from $2.3B a year earlier and eps grew 5.7% from $1.40.
Where can I find Zoetis's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001555280-26-000008) and the 10-K periodic report (0001555280-26-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.